ArticlemBio2010
Universal vaccines: shifting to one for many.
Article in mBio, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of amSphere · 2024Article
- COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Review
- Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi.Microorganisms · 2021Review
- Protective effect of fungal extracellular vesicles against murine candidiasis.Cellular microbiology · 2020Article
- Advances in Fungal Peptide Vaccines.Journal of fungi (Basel, Switzerland) · 2020Review
- Article
- The surge of universal influenza vaccines.Pathogens and global health · 2017Article
- A universal mammalian vaccine cell line substrate.PloS one · 2017Article
- Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.Journal of fungi (Basel, Switzerland) · 2016Article
- Development of vaccines for Candida albicans: fighting a skilled transformer.Nature reviews. Microbiology · 2013Article
- Simple polysaccharides and global responses in the era of vaccinomics.Pathogens and global health · 2013Article
- Vaccines against Coccidioides.The Korean journal of internal medicine · 2013Review
- Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis.PloS one · 2013Article
- Universal fungal vaccines: could there be light at the end of the tunnel?Human vaccines & immunotherapeutics · 2012Review
- Dendritic cells in antifungal immunity and vaccine design.Cell host & microbe · 2012Review
- Article
- New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges.Frontiers in microbiology · 2012Article
- Antibody Peptide based antifungal immunotherapy.Frontiers in microbiology · 2012Article
- Host defense pathways against fungi: the basis for vaccines and immunotherapy.Frontiers in microbiology · 2012Article
- Vaccine production, distribution, access, and uptake.Lancet (London, England) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human vaccines, with their exquisite antigenic specificity, have greatly helped to eliminate or dramatically abate the incidence of a number of historical and current plagues, from smallpox to bacterial meningitis. Nonetheless, as new infectious agents emerge and the number of vaccine-preventable diseases increases, the practice and benefits of single-pathogen- or disease-targeted vaccination may be put at risk by constraints of timely production, formulation complexity, and regulatory hurdles. During the last influenza pandemic, extraordinary efforts by vaccine producers and health authorities have had little or no influence on disease prevention or mitigation. Recent research demonstrating the possibility of protecting against all influenza A virus types or even phylogenetically distant pathogens with vaccines based on highly conserved peptide or saccharide sequences is changing our paradigm. "Universal vaccine" strategies could be particularly advantageous to address protection from antibiotic-resistant bacteria and fungi for which no vaccine is currently available.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.